Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

GABA‐mimetic drugs enhance apomorphine‐induced contralateral turning in rats with unilateral nigrostriatal dopamine denervation: Implications for the therapy of Parkinson's disease

GABA‐mimetic drugs enhance apomorphine‐induced contralateral turning in rats with unilateral... The underlying mechanisms responsible for advanced Parkinson's disease's becoming refractory to dopamimetic therapies are unclear. Postmortem brain studies indicate that patients with Parkinson's disease have decreased basal ganglia γ‐aminobutyric acid (GABA) function in addition to profound striatal dopamine (DA) deficiencies. In experimental animals, GABA‐utilizing striatal and nigral projection neurons appear to mediate motor behaviors arising from the stimulation of striatal DA receptors by agonists. We have examined the ability of directly and indirectly acting GABA‐mimetic drugs to alter turning behavior elicited by administering apomorphine, a DA agonist, to rats with unilateral lesions of dopaminergic nigrostriatal neurons. Low doses of directly acting postsynaptic GABA agonists (progabide, 4,5,6,7‐tetrahydroisoxazolo(5,4‐c)pyridin—3‐01) or a neuronal GABA transport inhibitor (SKF 100330‐A) potentiate apomorphine‐induced turning. Higher doses of these agents or acute inhibition of GABA catabolism inhibits turning. Our results suggest that low doses of certain GABA‐mimetics will improve the responses of patients with Parkinson's disease to concurrent DA receptor agonist therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Neurology Wiley

GABA‐mimetic drugs enhance apomorphine‐induced contralateral turning in rats with unilateral nigrostriatal dopamine denervation: Implications for the therapy of Parkinson's disease

Loading next page...
 
/lp/wiley/gaba-mimetic-drugs-enhance-apomorphine-induced-contralateral-turning-BRDI0CdgvI

References (32)

Publisher
Wiley
Copyright
Copyright © 1987 American Neurological Association
ISSN
0364-5134
eISSN
1531-8249
DOI
10.1002/ana.410210108
pmid
3827213
Publisher site
See Article on Publisher Site

Abstract

The underlying mechanisms responsible for advanced Parkinson's disease's becoming refractory to dopamimetic therapies are unclear. Postmortem brain studies indicate that patients with Parkinson's disease have decreased basal ganglia γ‐aminobutyric acid (GABA) function in addition to profound striatal dopamine (DA) deficiencies. In experimental animals, GABA‐utilizing striatal and nigral projection neurons appear to mediate motor behaviors arising from the stimulation of striatal DA receptors by agonists. We have examined the ability of directly and indirectly acting GABA‐mimetic drugs to alter turning behavior elicited by administering apomorphine, a DA agonist, to rats with unilateral lesions of dopaminergic nigrostriatal neurons. Low doses of directly acting postsynaptic GABA agonists (progabide, 4,5,6,7‐tetrahydroisoxazolo(5,4‐c)pyridin—3‐01) or a neuronal GABA transport inhibitor (SKF 100330‐A) potentiate apomorphine‐induced turning. Higher doses of these agents or acute inhibition of GABA catabolism inhibits turning. Our results suggest that low doses of certain GABA‐mimetics will improve the responses of patients with Parkinson's disease to concurrent DA receptor agonist therapy.

Journal

Annals of NeurologyWiley

Published: Jan 1, 1987

There are no references for this article.